局部晚期头颈鳞癌大分割对比常规分割加速放疗联合或不联合顺铂的III期随机非劣效试验
HYPNO试验是一项多中心、实用、嵌入式、双臂、非盲、随机对照非劣效III期研究,纳入792例局部晚期头颈鳞癌患者,随机接受20次55 Gy大分割放疗或33次66 Gy加速常规分割放疗,可联合每周35 mg/m2顺铂。大分割方案在局部区域肿瘤控制和3级及以上晚期不良事件两方面均通过非劣效检验,3年绝对差异≤1.4个百分点。
要点
- 大分割55 Gy/20次/4周方案在局部区域控制和晚期毒性上非劣效于66 Gy/33次/5.5周加速常规分割。
- 两组3年总生存、无进展生存、局部区域控制和3级及以上晚期不良事件绝对差异均≤1.4个百分点。
- 计划亚组分析未显示两组局部区域控制效应估计存在统计学显著异质性。
核心结论
- HYPNO试验组大分割方案在局部区域肿瘤控制和3级及以上晚期不良事件方面均被证明非劣效。
研究设计与样本
- 多中心、实用、嵌入式、双臂、非盲、随机对照非劣效III期试验,双主要终点为局部区域肿瘤控制和3级及以上晚期不良事件,非劣效界值均为10%。
- 2014年3月至2020年2月共792例患者中央随机,大分割组395例、常规分割组397例,计划样本量836例,实际入组94.7%。
- 允许同步每周35 mg/m2顺铂化疗,12个中心参与并按与试验方案一致的标准治疗执行。
主要发现
- 大分割组通过局部区域肿瘤控制非劣效检验(P = .04)和3级及以上晚期不良事件非劣效检验(P = .004)。
- 3年时两组总生存、无进展生存、局部区域控制和3级及以上晚期不良事件的绝对差异均≤1.4个百分点。
- 计划亚组分析显示两组局部区域控制效应估计无统计学显著异质性。
关键数值与推荐
- 大分割方案:55 Gy分20次,每周5次,共4周。
- 常规分割方案:66 Gy分33次,每次2 Gy,每周6次,共5.5周。
- 同步化疗为每周35 mg/m2顺铂。
- 双主要终点非劣效界值均为10%。
临床怎么用
- 对于局部晚期头颈鳞癌,可考虑采用55 Gy/20次/4周大分割放疗替代66 Gy/33次加速常规分割放疗,局部控制与晚期毒性均不劣于后者。
- 同步每周35 mg/m2顺铂在上述两种分割方案下均可使用。
局限性
- 因COVID-19疫情,实际入组792例,低于计划样本量836例(94.7%)。
- 研究为非盲设计。
- 各中心按与试验方案一致的标准治疗执行,可能存在中心间实践差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Based on bioeffect modeling of published outcomes after radiation therapy for head and neck squamous cell carcinoma with various time-dose-fractionation, we hypothesized that a 20-fraction hypofractionated (HFX) schedule delivering 55 Gy in 20 fractions, 5 fractions per week, over 4 weeks would be noninferior to a 33-fraction accelerated, normofractionated (NFX) 2 Gy per fraction schedule, delivering 66 Gy in 2-Gy fractions, 6 fractions per week over 5.5 weeks with respect to both local tumor control and late adverse events. METHODS AND MATERIALS: The HYPNO (HYPo-fractionated vs NOrmo-fractionated radiation therapy for head and neck squamous cell carcinoma) trial was designed as a multicenter, pragmatic, embedded, 2-arm, unblinded, randomized controlled noninferiority trial with dual primary endpoints, loco-regional tumor control, and grade 3 or higher late adverse events with a 10% noninferiority margin for both endpoints. The trial was open for enrollment in 12 centers, each adhering to their standard of care to the extent that it was consistent with the requirements of the trial protocol. Concurrent chemoradiation therapy with 35 mg/m2 cisplatin weekly was permitted. RESULTS: Between March 2014 and February 2020, 792 patients were centrally randomized: 395 to HFX and 397 to NFX. Accrual closed, with all outcome data still blinded, with 792 of a planned 836 patients (94.7%) enrolled, in part due to the emerging COVID-19 pandemic. The HYPNO test arm passed the separate noninferiority tests for both loco-regional tumor control (P = .04) and grade 3+ late adverse events (P = .004). At 3 years, the absolute difference in outcome between the 2 arms was ≤1.4 percentage points for overall survival, progression-free survival, loco-regional control, and grade 3+ late adverse events. The planned subgroup analyses showed no statistically significant heterogeneity of effect estimates for loco-regional control between the 2 trial arms. CONCLUSIONS: The HYPNO test arm schedule was shown to be noninferior with respect to both loco-regional tumor control and grade 3+ late adverse events.
引用
- Bentzen SM, Gupta T, Jacinto AA, et al. Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 41711624. doi:10.1016/j.ijrobp.2025.12.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。